After 2 doses of the vaccine, 83% of cancer patients who hadn’t previously been infected with the virus had detectable neutralising antibodies effective against the original strain of SARS-CoV-2, but only 54% against the Delta variant.People with cancer had no or few neutralising antibodies – antibodies that can block the virus entering cells – after their first dose, but levels rose after a second dose.
